Researchers at Albert Einstein College of Medicine of Yeshiva University have been awarded a $12 million grant from the National Institutes of Health (NIH) to develop a drug-impregnated intravaginal ring to prevent HIV infection in women.
As we move into the fourth decade of the HIV pandemic, the disease is having its greatest impact on women, particularly in sub-Sahara Africa, says principal investigator Betsy Herold, MD, professor of pediatrics, of microbiology & immunology, and of obstetrics & gynecology and womens health at Einstein and attending physician of pediatrics, The Childrens Hospital at Montefiore.
According to UNAIDS, approximately 34 million people are living with HIV worldwide. Sub-Saharan Africa is the region most affected and accounts for 69 percent of all people living with HIV.
To protect these women and slow the epidemic, we urgently need safe and effective prevention strategies, saysHerold.
Herold and co-investigator Patrick Kiser, PhD, a bioengineer at the University of Utah, previously developed an intravaginal ring that delivers a potent antitretroviral drug for more than four weeks and proved highly active against HIV in laboratory studies. But learning whether the devices preclinical performance will translate into real-world effectiveness has proven difficult.
The ideal intravaginal ring must release sufficient concentrations of drug to protect women at increased risk of HIV infection. And it will contain drugs that are:
active in the vagina, cervix and rectum
capable of both rapid and sustained drug delivery for at least one month
effective against many different HIV subtypes
safe
inexpensive
stable without needing refrigeration
The five-year project will determine if the drug released from the ring retains anti-HIV activity in the presence of vaginal secretions. In addition, studies involving non-human primates aimed at optimizing the vaginal rings design will be conducted at the Centers for Disease Control and Prevention.
In tests to see if two drugs work better than one, the ring will be impregnated with a second drug that inhibits HIV through a mechanism different from the first drug. A clinical study to assess the rings safety will also be carried out; this part of the project will include U.S. women taking oral contraceptives.
The grant will also fund a clinical study to assess safety and pharmacokinetics in women on Depo Provera in Kenya (led by Jeanne Marrazzo, MD, MPH, from the University of Washington, and Nelly Mugo, MPH, from Kenyatta National Hospital) and in U.S. women on oral contraceptive pills (led by Marla Keller, MD, associate professor of medicine and of obstetrics & gynecology and womens health at Einstein and attending physician of medicine at Montefiore Medical Center, the University Hospital for Einstein).
Were optimistic that the intravaginal approach to preventing HIV infection will overcome the problem of having to remember to use oral or gel products daily and will empower women to protect themselves against HIV, says Herold.
Herold has worked extensively to translate laboratory research into effective real-world preventive measures for HIV. She previously developed a laboratory test that predicts whether microbicides against HIV are safe for human use.
This five-year grant, Drug at the Right Place & Concentration: Optimizing Combination Vaginal Ring PrEP (U19AI103461), was awarded by National Institute of Allergy and Infectious Diseases, part of the NIH.
Source: Albert Einstein College of Medicine of Yeshiva University
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.